Back to Nephrology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Glomerular Diseases

Overview

Spherix’s coverage of the glomerular disease market concentrates on the current treatment efforts, as well as the potential promising therapies on the horizon, for FSGS, IgA nephropathy, Alport Syndrome, and membranous nephropathy patients. Market trending reports coupled with patient chart audits and launch trackers provide unique and invaluable insights into these rapidly advancing markets.

Services Available

Exploring the patient journey

  • Alport Syndrome (US)

  • Focal Segmental Glomerulosclerosis (US)

  • IgA Nephropathy (US)

  • Membranous Nephropathy (US)

Prepping for the pipeline

  • Alport Syndrome (EU)

  • Atypical Hemolytic Uremic Syndrome (US)

  • Complement Disorders (US)

  • Focal Segmental Glomerulosclerosis (FSGS) (US)

  • Focal Segmental Glomerulosclerosis (FSGS) (EU)

  • IgA Nephropathy (US)

  • IgA Nephropathy (EU)

  • Membranous Nephropathy (US)

  • Membranous Nephropathy (EU)

Benchmarking new brand performance

  • Nefecon (Calliditas) in IgA Nephropathy (US)

  • Bardoxolone Methyl (Reata) in Alport Syndrome (US)

GAUGING IMPACT OF DISRUPTIVE EVENTS

  • Nephrology Biosimilars Today and Tomorrow (US)

  • Renal Pipeline Tracker

  • Feedback from ASN Conference 2022 (US)

  • Nephrologist Feedback on [Current Market Event] (ongoing based on industry updates)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Glomerular Diseases Coverage